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The analysis of autophagy in cells and tissue has principally 
been performed via qualitative measures. These assays identify 
autophagosomes or measure the conversion of LC3I to LC3II. 
However, qualitative assays fail to quantitate the degradation of 
an autophagic substrate and therefore only indirectly measure an 
intact autophagic system. “Autophagic flux” can be measured using 
long-lived proteins that are degraded via autophagy. We developed a 
quantifiable luciferase reporter assay that measures the degradation 
of a long-lived polyglutamine protein aggregate, polyQ80-luciferase. 
Using this reporter, the induction of autophagy via starvation 
or rapamycin in cells preferentially decreases polyQ80-luciferase 
when compared with a nonaggregating polyQ19-luciferase after 
four hours of treatment. This response was both time- and concen-
tration-dependent, prevented by autophagy inhibitors and absent 
in ATG5 knockout cells. We adapted this assay to living animals 
by electroporating polyQ19-luciferase and polyQ80-luciferase 
expression constructs into the right and left tibialis anterior (TA) 
muscles of mice, respectively. The change in the ratio of polyQ80-
luciferase to polyQ19-luciferase signal before and after autophagic 
stimulation or inhibition was quantified via in vivo biolumines-
cent imaging. Following two days of starvation or treatment with 
intraperitoneal rapamycin, there was a ~35% reduction in the ratio 
of polyQ80:polyQ19-luciferase activity, consistent with the selec-
tive autophagic degradation of polyQ80 protein. This autophagic 
response in skeletal muscle in vivo was abrogated by co-treatment 
with chloroquine and in ATG16L1 hypomorphic mice. Our study 
demonstrates a method to quantify the autophagic flux of an 
expanded polyglutamine via luciferase reporters in vitro and in 
vivo.
Introduction
Macroautophagy, herein referred to as autophagy, is a means by 
which cells degrade long-lived proteins and organelles.1 Many inher-
ited as well as sporadic diseases such as Alzheimer disease, Parkinson 
disease and skeletal myopathies may be due to impaired autophagy.2 
Cells sequester regions of cytoplasm within a double-membrane 
bound structure defined as an autophagosome. Autophagosomes fuse 
with lysosomes allowing the proteolytic digestion of their contents. 
Several methods to quantitate the induction of autophagy in cells 
and tissue have been developed and extensively reviewed.3 The 
identification of autophagosomes via electron microscopy or using 
autophagosomal markers such as microtubule-associated protein 
1 light chain 3 (LC3) allow the monitoring of autophagosome 
formation. Other means include quantifying the upregulation of 
autophagic proteins or the conjugation of ATG12 to ATG5, a critical 
step in the autophagic cascade, via immunoblot. However, none of 
these methods evaluate “flux” through the autophagic system.3
To get around this, dual fluorescent reporter constructs containing 
a pH-sensitive and insensitive fluorescent tag have been used to 
evaluate the fusion of autophagosomes with lysosomes in living cells 
and more recently on serially examined fixed tissue.4 These methods 
rely on qualitative identification of fluorescent punta and are at 
best semiquantitative. Other means of evaluating “autophagic flux” 
identify the degradation of substrates that are degraded primarily 
via autophagy in the presence of autophagy inducers and inhibi-
tors. For example the degradation of LC3II or p62/sequestosome 
are proposed to be reliable markers of autophagic flux.3 Similarly, 
the release of radiolabeled amino acids from cultured cells measures 
global autophagic flux of long-lived protein substrates. Finally, the 
degradation of protein aggregates such as expanded polyglutamine 
containing proteins or disease-associated mutations in α-synuclein 
are reported to be preferentially degraded via autophagy.3 While 
these assays measure autophagic flux and are more quantitative than 
the microscopic identification of autophagosomes, they can only be 
performed on tissue culture cells or tissue homogenates. In addition, 
they are not readily amenable to high throughput assays.
The identification of autophagy and quantitating “autophagic 
flux” in live mammalian tissue is problematic. Immunostaining of 
animal tissue with antibodies to autophagy markers or the use of 
GFP-LC3 transgenic mice can reveal an accumulation of autopha-
gosomes in the setting of impaired autophagy, although a similar 
pattern can be seen with upregulated yet intact autophagy.3 Similarly, 
the accumulation of processed LC3II on immunoblot does not 
discriminate between an increase in LC3 production or a decrease 
in autophagic degradation.5 These limitations make it difficult to 
interpret “autophagic flux” in living animal tissue.
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To circumvent these limitations in mammalian tissue, we devel-
oped autophagy-selective luciferase reporters that are visualized using 
in vivo bioluminescence imaging of living mouse skeletal muscle. 
By comparing the steady-state changes of two luciferase reporters, 
polyQ80-luciferase and control polyQ19-luciferase, each electropo-
rated into separate muscles of mice, we can quantitate “autophagic 
flux” in a live animal following autophagic stimuli. Our reporter 
system can be used in vitro and in vivo to quantitate the induc-
tion and inhibition of “autophagic flux.” These reporters provide 
a dynamic and specific tool for the analysis of autophagy in health 
and disease.
Results
We engineered luciferase reporter constructs that comprised 
firefly luciferase fused to an N-terminal polyglutamine with either 19 
(polyQ19-luciferase) or 80 (polyQ80-luciferase) repeats. Following 
transfection of U20S cells with polyQ19-luciferase, immunofluo-
rescence with a luciferase antibody demonstrated expression with 
a diffuse cellular localization pattern throughout the cell (Fig. 1A, 
top). In contrast, polyQ80-luciferase was localized to small peri-
nuclear inclusions that strongly colocalized with an antibody to 
ubiquitinated proteins (Fig. 1A, bottom). These data suggested that 
polyQ80-luciferase aggregated in cells similar to other previously 
reported polyQ80 constructs.6 To confirm that polyQ80-luciferase 
was degraded in an autophagy-dependent manner, we performed 
western blot analysis with a  anti-luciferase antibody of lysates from 
polyQ80-luciferase and polyQ19-luciferase expressing U20S cells 
before and after 6 hours of nutrient deprivation (starvation) or the 
addition of 20 μg/mL rapamycin, 50 μg/mL hydroxychloroquine 
or 100 ng/mL bafilomycinA (Fig. 1B). Similar to that previously 
reported with other expanded polyglutamine-containing expression 
constructs, starvation and rapamycin selectively decreased polyQ80-
luciferase protein levels.7,8 Chloroquine and bafilomycinA showed a 
modest increase in polyQ80-luciferase levels after 6 hours.
We transfected U20S cells with either polyQ19-luciferase (Fig. 
1C) or polyQ80-luciferase (Fig. 1D) and induced autophagy via 
nutrient deprivation for 4 hours with and without the co-application 
of 20 μM of the autophagy inhibitor 3-methyladenine (3MA). Only 
the nutrient-deprived polyQ80-luciferase transduced cells had a 
significant reduction in luciferase activity (by ~50%) consistent with 
Figure 1. (A) U20S cells transiently transfected with polyQ19-luciferase 
(top) or polyQ80-luciferase (bottom) and immunostained with anti-luciferase 
(green) or anti-ubiquitin (red) antibodies. Note that polyQ80-luciferase forms 
small perinuclear ubiquitin positive inclusions while polyQ19-luciferase 
is diffuse throughout the cell. (B) Immunoblot using anti-luciferase or anti-
tubulin (loading control) of U20S lysates transfected with polyQ80-luciferase 
(top) and polyQ19-luciferase (bottom) following 6 treatment with nutrient 
deprivation (starvation) or rapamycin, chloroquine or bafilomycinA. Note 
that polyQ80-luciferase decreases in the starvation and rapamycin treated 
cell lysates. *is a nonspecific band seen in non-transfected cells. (C and D) 
Luciferase activity in U20S cells transfected with (C) polyQ19-luciferase or 
(D) polyQ80-luciferase and treated with nutrient deprivation for 4 hours or 
nutrient deprivation plus 20uM autophagy inhibitor 3-methyladenine (3MA). 
Only polyQ80-luciferase activity decreases with the induction of autophagy. 
**denotes a p value of <0.001. (E) Representative epifluorescent image of 
U20S transfected with GFP-LC3 expression plasmid following no treatment, 
nutrient deprivation (starv) or nutrient deprivation plus bafilomycinA (starv + 
bafA) for 4 hours. Note the increase in GFP-LC3 positive puncta in nutrient 
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(see in vivo studies) or treatments that affect the stability or expres-
sion of both polyQ19 and polyQ80 (see Fig. 3D using proteasome 
inhibition). Table 1 and Figure 2B show luciferase activity from 
differentiated C2C12 myotubes that were transfected with either 
polyQ19-luciferase or polyQ80-luciferase and treated with nutrient 
deprivation or rapamycin (10 μg/mL) for 18 hours. PolyQ80-
luciferase and the ratio of polyQ80/polyQ19 from cells treated with 
nutrient deprivation or rapamycin decreased by 70% and 37%, 
respectively, consistent with a selective degradation of polyQ80-
luciferase during autophagy. These changes were both time-and 
concentration-dependent as shown in Figure 3A in which cells were 
starved for 4 and 18 hours or in Figure 3B in which cells were treated 
with 2 μg/ml, 10 μg/ml or 50 μg/ml of rapamycin for 18 hours.
To determine if this assay was capable of quantitating autophagic 
inhibition, we transfected differentiated C2C12 myotubes with 
polyQ19-luciferase or polyQ80-luciferase and subsequently treated 
cells with escalating concentrations of the autophagic inhibitors 
chloroquine and bafilomycinA (Fig. 3C). As expected, the ratio 
of polyQ80/polyQ19 increased in both chloroquine and bafilo-
mycinA treated cells in a concentration-dependent manner. This 
was in contrast to treatment with the proteasome inhibitor, 
MG132, which increased the levels of both polyQ19-luciferase 
polypeptide degradation. This decrease was abolished by cotreatment 
with 20 μM 3MA. The decrease was not due to a decrease in cell 
number since identical experiments performed following cotransfec-
tion with Renilla luciferase showed no change in Renilla activity 
(data not shown). To demonstrate that we are in fact inducing 
autophagy in our experimental system, GFP autofluorescence is 
shown from U20S cells transfected with a GFP-LC3 expression 
construct9 following no nutrient deprivation, nutrient deprivation or 
nutrient deprivation plus bafilomycinA for 4 hours (Fig. 1E). Under 
basal conditions, GFP-LC3 is present throughout the cell with occa-
sional puncta. However under conditions of nutrient deprivation, 
GFP-LC3 redistributes to multiple puncta consistent with autopha-
gosome formation. These puncta are even more numerous when 
autophagosome fusion with lysosomes is inhibited with bafilomy-
cinA (Fig. 1E). This experiment also highlights a key difficulty with 
interpreting LC3 puncta formation since puncta are present in cells 
capable of autophagy and cells treated with an autophagy inhibitor.
To develop a simple quantifiable assay to measure changes in 
the “autophagic flux” of polyQ80, we devised a strategy that would 
analyze the ratiometric change in polyQ80-luciferase/polyQ19-
luciferase (Fig. 2A). By comparing the ratio of polyQ80/polyQ19, 
we control for variations in expression that may occur over time 
Figure 2. (A) Schematic representation of “autophagic flux” assay using the ratio of polyQ80-luciferase to polyQ19-luciferase activity. (B) Graphical repre-
sentation of luciferase activity from differentiated C2C12 myotubes transfected with polyQ19 or polyQ80-luciferase constructs and treated with autophagy 
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polyQ-19 expression was significantly elevated in untreated ATG5-/- 
MEFS (Fig. 3E). This decrease was abolished in ATG5-/- MEFs (Fig. 
3E). In addition, the ratio of polyQ80/polyQ19-luciferase expres-
sion at basal was significantly elevated in ATG5-/- MEFs (Fig. 3E). 
This may suggest that our assay is able to detect alterations in basal 
autophagy as well as induced autophagy.
These studies suggest that polyQ80-luciferase is selectively 
degraded via autophagic stimuli and that the change in the ratio 
of polyQ80/polyQ19 from its baseline is a measure of “autophagic 
flux.” We adapted this assay to living mouse skeletal muscle by using 
and polyQ80-luciferase to similar extents resulting in only a 
modest change in the ratio of polyQ80/polyQ19 luciferase (Fig. 
3D). Whether a similar phenomenon (i.e., a comparable decrease 
in luciferase activity between polyQ80-luciferase and polyQ19-
luciferase) occurs upon proteasome activation is not known.
We performed the same assay using ATG5+/+ and ATG5-/- mouse 
embryonic fibroblasts (MEFs).10 ATG5-/- MEFs lack ATG5 protein, 
are deficient in autophagy, and do not form autophagosomes upon 
nutrient deprivation.10 When subjected to nutrient deprivation for 
6 hours, ATG5+/+ MEFs had a 30% decrease in the ratio polyQ80/
Figure 3. The ratio of polyQ80/polyQ19-luciferase activity in differentiated C2C12 myotubes transfected following (A) starvation for 4 or 18 hours (B) 
increasing concentrations of rapamycin for 18 hours or (C) increasing concentrations of autophagy inhibitors chloroquine (CQ) or bafilomycinA (Baf). 
*denotes a p value of <0.01. **denotes a p value of <0.001. (D) U20S cells treated with proteasome inhibitor MG132 have a similar increase in both 
Q19 and Q80-luciferase activity after 4 hours of treatment. (E) ATG5+/+ or ATG5-/- mouse embryonic fibroblasts (MEFs) were transfected with polyQ80 or 
polyQ19-luciferase and subjected to nutrient deprivation for 0 or 6 hours. The raw ratio of polyQ80/polyQ19-luciferase activity is presented. Note that the 
amount ratio of polyQ80/polyQ19-luciferase is elevated in ATG5-/- cells at time 0. In addition, whereas the ratio decreases in ATG5+/+ MEFs following 
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in autophagy.11 We confirmed that these mice lack ATG16L1 in 
skeletal via immunoblot using anti-ATG16L1 antibody (Fig. 5A). 
Two changes were noticed in the ATG16L1 animals when compared 
to control littermates. The average polyQ80/polyQ19 ratio value 
was elevated in ATG16L1 animals on day 0 of imaging (day 2 post-
electroporation) suggesting an increase in polyQ80-luciferase protein 
as compared with polyQ19-luciferase protein levels (Figs. 4B and 
5B). This was not due to a decrease in polyQ19 activity levels. The 
average polyQ19-luciferase activity from one experiment using three 
control and three ATG16L1 animals was 2.3 x 105 RLU/min and 
2.4 x 105 RLU/min, respectively. In contrast, the average polyQ80-
luciferase activity from the same three control or ATG16L1 animals 
was 2.6 x 105 RLU/min and 4.5 x 105 RLU/min, respectively. 
Following one day of starvation, control animals had a 25% decrease 
in the ratio of polyQ80/polyQ19 in contrast to ATG16L1 animals 
which had a 6% increase that was statistically insignificant (Figs. 4B 
and 5B). These data suggest that ATG16L1 animals have impaired 
autophagic clearance of aggregate prone proteins under basal and 
induced conditions. Additionally, our assay using in vivo biolumines-
cence of aggregate prone luciferase reporters is able to detect changes 
in genetically modified animal models.
Discussion
The development of short-lived destabilized reporter constructs 
has been essential to the understanding of the ubiquitin-proteasome 
system (UPS) in vitro and in vivo.12-14 These constructs, when 
expressed in cells or tissue, provide an indirect readout of UPS 
activity.13 Similarly, fusion reporters of kinase substrates enable direct 
analysis of ligand-induced phosphorylation and subsequent ubiq-
uitin-dependent degradation of key regulators of signaling cascades, 
such as IκBα, using IκB-Fluc fusion reporters.15 However, analogous 
reporters have not been successfully developed for the other major 
degradation pathway in cells, macroautophagy. This may be due to 
the fact that autophagy indiscriminately degrades long-lived proteins, 
making it difficult to identify a suitable substrate. Recently, it has 
been shown that protein aggregates and inclusion bodies are prefer-
entially degraded via autophagy.6,8 More importantly, mechanisms 
that enhance autophagic degradation decrease inclusion bodies and 
improve cell survival in protein aggregate diseases.16
We have developed a luciferase reporter that measures the pref-
erential degradation of an aggregated protein, polyQ80-luciferase, 
and compares this to the degradation of a nonaggregated protein, 
polyQ19-luciferase. By inducing or inhibiting autophagy via various 
stimuli, we show that the ratiometric change in polyQ80-luciferase 
in vivo bioluminescent imaging. The right and left tibialis anterior 
(TA) from age and sex-matched C57/B6 mice were electroporated 
separately with 40 μg of polyQ80-luciferase or polyQ19-luciferase 
expression constructs. Baseline luciferase activity and a subsequent 
polyQ80/polyQ19 ratio for each animal was determined 2 days post-
electroporation (Fig. 4A). This ratio was arbitrarily set to 1.0 at time 
point 0. Select animals were treated with food deprivation alone, 
food deprivation with co-administration of chloroquine (10 mg/kg), 
or rapamycin (5 mg/kg) for one or two days. In our initial studies 
over two days of normal diet, untreated control animals had a mean 
decrease in the ratio of polyQ80/polyQ19 of 0.88 ± 0.13 (p = 0.9; n 
= 10 animals) as compared to 1.0 at time point 0. This suggests that 
the baseline ratio of polyQ80/polyQ19 does not change significantly 
over the course of two days.
In contrast, animals deprived of food (Fig. 4B and C) had a 25% 
and 34% reduction in the ratio of polyQ80/polyQ19 after 1 and 
2 days, respectively. This decrease was abolished by the co-admin-
istration of chloroquine. Chloroquine alone did not significantly 
change the ratio of polyQ80/polyQ19 after 2 days. Similar results 
were obtained after 2 days intraperitoneal injection of 5 mg/kg body 
weight of rapamycin (Fig. 4D).
To compare our findings using polyQ80/polyQ19-luciferase 
with other methods of measuring autophagic induction, we analyzed 
skeletal muscle lysates from similarly treated animals using immu-
noblot or immunohistochemistry with the autophagosome marker, 
p62. Total p62 protein levels increased in skeletal muscle from 
animals subjected to 2 days of nutrient deprivation (Fig. 4E). In 
addition, p62 puncta were not present in control mouse tibialis 
anterior muscle but were present in nutrient deprived and even more 
prominent in nutrient deprived plus chloroquine treatment (Fig. 
4F). These data confirm that under our experimental conditions, 
autophagy is induced in mouse TA skeletal muscle. More impor-
tantly, these data highlight the difficulty with interpretation and 
quantitation of autophagy using currently available methods. For 
example, although autophagy is impaired in the nutrient deprived 
plus chloroquine treated animal muscle it has an increase in p62 
puncta similar to the autophagy competent, nutrient-deprived 
animal muscle. GFP-LC3 puncta were also induced via nutrient 
deprivation in skeletal muscle when GFP-LC3 transgenic mice were 
used (data not shown).
To determine whether in vivo bioluminescent imaging could 
detect a decrease in autophagic flux in a genetically manipulated 
animal model deficient in autophagy, we performed similar experi-
ments in ATG16L1 hypomorphic mice which have a partial defect 
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affected at many steps. These steps include aggregate formation, 
protein aggregate trafficking to an inclusion body, protein ubiq-
uitination, autophagosome formation, lysosome fusion and finally 
degradation.18 The current assay does not distinguish between these 
intermediate steps; instead, it measures global protein aggregate flux 
through this pathway. Alterations at any of these steps would be 
expected to selectively affect the degradation of polyQ80-luciferase 
when compared to polyQ19-luciferase and therefore, the assay 
may not be specific for the final commitment to the autophagic 
process. For example, mechanisms that disaggregate a protein 
aggregate, facilitate proper folding of misfolded proteins, or impair 
trafficking to an inclusion body may alter polyQ80-luciferase levels 
and subsequent determination of autophagy activity, independent of 
formal autophagy, per se.
Nonetheless, our results suggest that autophagy induced via 
classical nutrient deprivation can be detected as early as 4 hours in 
cultured U20S cells and 6 hours in differentiated C2C12 cells using 
our assay. The decrease persisted in differentiated C2C12 cells after 
to polyQ19-luciferase activity is a sensitive, quantifiable and repro-
ducible measure of “autophagic flux” in cells and animals.
The degradation and clearance of aggregated proteins is thought to 
occur primarily via autophagy, although some may occur via protea-
somal degradation as well. Our assay does not specifically distinguish 
between degradative pathways, but rather reflects a change in 
steady-state protein aggregate clearance. By comparing the change in 
polyQ80-luciferase levels with polyQ19-luciferase levels, we are able 
to control for nonpreferential protein degradation that also affects 
nonaggregated proteins. Additionally, this controls for changes in 
protein translation and synthesis that have been reported to affect 
the interpretation of autophagic inducers such as rapamycin.17 It will 
be interesting to see if our assay also correlates with the autophagic 
degradation of other long-lived substrates or organelles or if the rate 
of degradation in our assay is specific to aggregated proteins. To our 
knowledge, this type of comparison has not yet been attempted due 
to the technical impediment of quantitating “autophagic flux.”
Overall degradation and clearance of protein aggregates can be 
Figure 4 (See previous page for parts A–D)). (A) Diagram of 
imaging paradigm. Mice were electroporated with polyQ80 
and polyQ19-luciferase constructs into the right and left TA 
muscle respectively. Two days postelectroporation (day 0 or 
pre-treatment group) the ratio of polyQ80/polyQ19-luciferase 
activity was determined for each animal. Each cohort of animals 
was subsequently treated with autophagic stimulus for one and 
two days (post-treatment). After treatment, the ratio of polyQ80/
polyQ19-luciferase activity was again determined for each ani-
mal and the change was plotted. (B) Sample images of control 
or ATG16L1 hypomorphic mice before (pretreatment) and after 
food deprivation (post-treatment). (C) Six animals in each of 4 
groups were electoporated and then were fed, starved, starved 
plus treated with intraperitoneal chloroquine or treated with 
chloroquine alone for two days. Only the starved animal group 
had a significant decrease of ~34% in the ratio of polyQ80/
polyQ19-luciferase activity. (D) 12 animals were electroporated 
and half received no treatment or were treated with rapamycin 
for one and two days. Only the rapamycin treated animals had a significant decrease of ~30%. (E) Immunoblot analysis of skeletal muscle lysates (tibialis 
anterior, gastrocnemius or triceps) from mice fed (F) or following 2 days of nutrient deprivation (S), using a p62 antibody. α-tubulin is shown as a loading 
control. (F) Tibialis anterior skeletal muscle was isolated from fed or animals nutrient deprived or nutrient deprived and treatment with chloroquine for 2 
days and flash frozen in liquid nitrogen cooled isopentane. 8 μM sections were immunostained with anti-p62 antibody. All images are taken at the same 
exposure. Inset shows magnification of boxed region.
Figure 5. (A) Immunoblot of skeletal 
muscle lysate (gastrocnemius or tibialis 
anterior) from wild-type and ATG16L1 
hypomorphic mice using an ATG16L1 
antibody. (B) A similar experiment as 
above was performed using 11 control 
or 7 ATG16L1 hypomorphic mice. The 
average polyQ80-luciferase/polyQ19-
luciferase ratio for each animal is plot-
ted. ATG16L1 mice have higher ratio and 
have a persistently elevated ratio follow-
ing one day of starvation (6% increase 
from day 0), whereas control animals had 
a 25% decrease in polyQ80/polyQ19-
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a change in the degradation of polyQ80-luciferase following 6 
hours of rapamycin treatment (not shown).22 This was in contrast 
to nutrient deprivation which decreased the ratio of polyQ80-
luciferase/polyQ19-luciferase after only 6 hours. These data suggest 
that rapamycin may induce autophagy via other mechanisms such 
as transcriptional changes to autophagy related proteins in skeletal 
muscle as previously suggested.22
In summary, we have developed a quantifiable method for 
evaluating “autophagic flux” of protein aggregates in vitro and in 
vivo. This technique may be especially valuable to identify impaired 
autophagic degradation in situations where the accumulation of 
autophagosome markers can be consistent with increased autophagy 
or alternatively impaired autophagic degradation. Additionally, our 
technique is amenable to high throughput assay development and 
may be useful in identifying compounds that preferential enhance 
the clearance of protein inclusions. The efficacy of these compounds 
can be further tested in live animal models.
Methods
Plasmids and cell culture. PolyQ-luciferase constructs were gener-
ated as follows: firefly luciferase was excised from IκB-luciferase15 
with BamHI and NotI and subcloned in polyQ19 or polyQ80-CFP 
constructs after removal of CFP with XbaI and NotI. Luciferase anti-
body was purchased from Sigma (St. Louis, Missouri). p62 antibody 
was purchased from Abgent (San Diego, California). Osteosarcoma 
U20S cells and the mouse myoblast cell line C2C12 (American 
Type Culture Collection, Rockville, Maryland) were maintained 
at 37°C/5% CO2 in Dulbecco’s modified Eagle’s medium (Sigma) 
supplemented with 10% fetal bovine serum, 50 μg/ml penicillin and 
50 μg/ml streptomycin. ATG5+/+ and -/- MEFS and the GFP-LC3 
expression plasmid were obtained from Dr. Herbert Virgin.
Induction and inhibition of autophagy. To induce autophagy 
in vitro, cells were rinsed 2 times in Hanks’ balanced salt solution 
(HBSS) and then incubated in HBSS as a starvation medium either 
4, 6 h or 18 h. Autophagy was also induced by administration 
of the mTOR specific inhibitor, rapamycin (Sigma), in the final 
concentration of 10 μg/ml. For dose experiments, low concentra-
tion rapamycin was 2 μg/ml and high dose was 50 μg/ml. Three 
chemical inhibitors were employed to block autophagy in U20S and/
or C2C12 cells. These includes hydroxychloroquine (30 μg/ml) and 
bafilomycin A1 (200 ng/ml) which interfere with the fusion between 
autophagosomes and lysosomes. For low treatment, we used 6 μg/ml 
hydroxychloroquine and 40 ng/ml bafilomycinA1. For high concen-
tration treatments, we used 150 μg/ml chloroquine and 1 μg/ml of 
bafilomycinA1. 3-Methyladenine (3-MA) prevents the formation 
of autophagosomes and was used at 20 mM. For in vivo autophagy 
induction, mice were starved up to 48 h or dosed with intraperi-
toneal injections of rapamycin (5 mg/kg body weight) daily for 2 
days. Hydroxychloroquine (10 mg/kg body weight) was i.p. injected 
two times daily for 2 days to inhibit autophagy. All chemicals were 
purchased from Sigma.
Animals. 3–4 month old female C57/B6 mice were used for each 
experiment except for ATG16L1 mice (11) which were 4 months 
old and compared with littermate controls. In the case of starva-
tion experiments, 6 animals were used per condition and data was 
from three independent experiments. For rapamycin experiments, 
4 animals per condition were used in two independent experiments 
and for ATG16L1 experiments, 5 animals per condition were used 
18 hours. This did not reflect enhanced cell death since nutrient 
deprivation did not change polyQ19-luciferase levels or the activity 
of a cotransfected, nonregulated Renilla luciferase reporter (not 
shown). This finding is consistent with other studies demonstrating 
conversion of LC3I to LC3II or GFP-LC3 puncta formation.9
We adapted our in vitro luciferase assay to living animals by elec-
troporating mouse tibialis anterior with either polyQ80-luciferase 
or polyQ19-luciferase. Electroporation of plasmid DNA is an 
effective and efficient means of expressing exogenous protein in 
skeletal muscle.19 Expression of plasmid DNA in skeletal muscle via 
electroporation is affected by multiple variables.19 These variables 
include concentration and purity of plasmid DNA, volume of injec-
tion, and electroporation parameters. In addition, higher voltage 
electroporation results in significant tissue damage and diminished 
reporter expression. Since our sensitivity for luciferase detection was 
well above threshold, we were able to use a low voltage electropora-
tion paradigm which resulted in minimal tissue damage as evaluated 
via histochemical analysis post-injection (data not shown). In fact, 
luciferase gene expression via in vivo bioluminescence is detectable 
at 2 days following direct naked plasmid DNA injection into mouse 
muscle without electroporation (personal observations).
In our experimental paradigm, each animal serves as its own 
control. For example the right TA is electroporated with polyQ80-
luciferase and the left TA with polyQ19-luciferase. Therefore, any 
intervention that is performed on the whole animal, such as starva-
tion or drug treatment, affects both the right and left limbs equally. 
In addition, since the ratio of polyQ80-luciferase to polyQ19-
luciferase is variable from animal to animal, each animal is initially 
imaged at time point 0 (day 2 post-electroporation) and subsequent 
ratios are taken on days 1 or 2. The change in the ratio of polyQ80/
polyQ18 luciferase activity is then compared for each animal and 
compared to the treatment group.
The ratio of polyQ80/polyQ19-luciferase had a small insignificant 
decrease in a cohort of 10 fed, untreated animals after 2 days. This 
subtle decrease suggests that polyQ80-luciferase may be degraded to 
a greater degree over time when compared with polyQ19-luciferase; 
a larger cohort of animals may be needed to confirm this finding. 
Other alternatives include an increase in myocyte death due to 
polyQ80-luciferase toxicity or perhaps polyQ80-luciferase expression 
induces autophagy independently of other treatments as has previ-
ously been reported.20,21
Interestingly, ATG16L1 hypomorphic mice and ATG5-/- MEFs 
had an overall increase in the ratio of polyQ80-luciferase/polyQ19-
luciferase before the stimulation of autophagy. Therefore, these 
autophagy deficient mice and cells have more polyQ80-luciferase 
protein/polyQ19-luciferase protein than wild-type control mice and 
ATG5+/+ MEFS. These results are consistent with a decrease in basal 
“autophagic flux” and suggest that our assay is capable of quanti-
tating low levels of unstimulated autophagy.
Our study stimulated autophagy in mouse skeletal muscle via 
traditional mechanisms such as starvation and the mTOR inhibitor, 
rapamycin. We found that intraperitoneal rapamycin was able to 
selectively enhance the degradation of polyQ80-luciferase in mouse 
skeletal muscle. Consistent with this, C2C12 myotubes treated with 
rapamycin also had a selective degradation of polyQ80-luciferase, 
with the ratio of polyQ80-luciferase/polyQ19-luciferase decreasing 
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as a baseline was calculated for each independent animal. Statistical 
analysis was performed using paired student t-tests by comparing 
the ratiometric change from each animal in control and treatment 
groups.
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in two independent experiments. 3 month old GFP-LC3 mice were 
obtained from the laboratory of Dr. Herbert Virgin.
In vitro luciferase assay. U20S and C2C12 myoblasts were trans-
fected with either 1.5 μg polyQ19-luciferase or polyQ80-luciferase 
vector using lipofectamine2000 (Invitrogen) according to manufac-
turer’s protocol. In some cases, Renilla luciferase control reporter 
vector (pRL-TK) (Promega) was transfected at the same time for 
comparison. U20S cells were harvested 36 hours post-transfection 
and after treatment with starvation or rapamycin for 4 hours. For 
C2C12 myoblasts, 24 h post-transfection, cell media were changed 
to media containing 2% horse serum for differentiation. After 4–5 
days of differentiation, C2C12 myotubes were treated with various 
chemicals and/or starvation with HBSS media to induce and/
or inhibit autophagy for either 6 h or 18 h, thereafter lysed with 
passive lysis buffer (Promega) for 15 min at room temperature. One 
hundred microliters of lysates were pipetted into 96-well plates in 
triplicate. Luciferase activities of the resulting lysates were assessed 
with a luciferase assay system (Promega), according to manufac-
turer’s instructions by using a microplate luminometer with injectors 
(Molecular Devices). Data were expressed as either relative light units 
or as the ratio of polyQ80-luciferase to polyQ19-luciferase lumines-
cence signal values.
In vivo electroporation and bioluminescent imaging of mice. 
Animal protocols were approved by the Animal Studies Committee 
of Washington University School of Medicine. Mice were anesthe-
tized using pentobarbital (50 mg per kg body weight). The skin 
overlying the tibialis anterior (TA) muscle was shaved, and the 
animals were injected with endotoxin free polyQ19-luciferase (left 
leg, 25 μg) or polyQ80-luciferase (right leg, 25 μg) diluted in sterile 
PBS to a volume of 50 μl by using a 0.5 ml syringe fitted with a 
29-gauge needle. Two-needle array electrodes (BTX, San Diego, 
California) were inserted into the muscle immediately after DNA 
delivery for electroporation. The distance between the electrodes 
was 5 mm, and the array was inserted longitudinally relative to the 
muscle fibers. In vivo electroporation parameters were the following: 
voltage, 75 V; pulse length, 50-ms; # of pulse, 6 pulses; pulse 
interval, 200 msec; desired field strength, 200 V/cm, given by a BTX 
ECM830 Electro Square Porator. After 2 days of recovery, mice were 
anesthetized (isoflurane), and bioluminescence imaging with a CCD 
camera (IVIS imaging system, Caliper) was initiated 10 min after 
i.p. injection of d-luciferin (150 μg per g of body weight) for muscle 
polyQ-luciferase expression. Luminescent images were obtained 
using the same exposure time for each individual experiment, 2–5 
min; binning, 2–8; no filter; f-stop, 1; FOV, 10 cm. After pretreat-
ment imaging, mice were treated with rapamycin, chloroquine and/
or starvation, or saline for the control group. Post-treatment imaging 
was performed at 24 h and 48 h treatments after i.p. injection of 
d-luciferin at each of those times. Regions of interest were defined 
manually over the TA muscles for determining total photon flux 
(photons per second). Data is expressed as a ratio of polyQ80-
luciferase to polyQ19-luciferase photon values.
Statistical analysis. For in vitro studies, individual transfections 
were treated as independent experiments and unpaired student 
t-tests were performed on treatment versus non-treatment groups. 
All in vitro studies were performed in triplicate and repeated on three 
independent occasions. For in vivo studies, the change in the ratio 
of polyQ80/polyQ19 for each animal using the pretreatment value 
